NewsBenzingaBelite Bio presenta domanda di autorizzazione all’immissione in commercio a Singapore, nel Regno Unito e in Svizzera per Tinlarebant per il trattamento della malattia di Stargardt di tipo 1 Belite Bio presenta domanda di autorizzazione all’immissione in commercio a Singapore, nel Regno Unito e in Svizzera per Tinlarebant per il trattamento della malattia di Stargardt di tipo 1 Benzinga 2026.10.14 20:04 (GMT+0) Open on Benzinga Other news Ant Group Digital Technologies releases decision model LingDT-Decision-1.0, outperforming Microsoft and JEV models in accuracy What You Need to Know Ahead of American Water Works’ Earnings Release Robinhood plans to launch retail investment platform in the Middle East next year Trump: Data Center Companies Should Pay "Dividends" to Host Communities Estrella Immunopharma (ESLA) Stock Soars 18%: What’s Driving the Surge Stock Market: Will S&P 500 Open Up or Down Today?
Ant Group Digital Technologies releases decision model LingDT-Decision-1.0, outperforming Microsoft and JEV models in accuracy
